Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.64898/2026.10.12.758523

AT1R-Selective Negative Allosteric Modulator Targeting the Epitope for Pathogenic Autoantibody Activation

Singh, K. D.·Pardhi, T. R.·Harford, T. J.·Laishram, L.·Ravi, T.·Desnoyer, R.·Maroo, A. P.·Tang, W. W. H.·Karnik, S. S.
View original source ↗Export metadata ↓

Abstract

A major therapeutic strategy for managing cardiovascular and renal diseases is the use of angiotensin receptor blockers (ARBs). These drugs block both pathogenic and physiological signaling by the angiotensin II type 1 receptor (AT1R) by preventing angiotensin II (AngII) binding to orthosteric pocket in transmembrane portion of AT1R. However, in many autoimmune diseases, AT1R activation is chronically driven by pathogenic autoantibody binding to a distinct extracellular surface located allosteric site. Currently, there are no allosteric inhibitors of AT1R available to mechanistically prevent the autoantibodies and preserve the orthosteric hormonal functions of AngII. Here, we report the structure-guided hit-to-lead optimization of TP1, a first-in-class AT1R allosteric chemotype and negative allosteric modulator (NAM) with improved potency and drug-like properties. Computational docking and site-directed mutagenesis identified a TP1 binding mode that is distinct from the orthosteric-site binding of ARBs and AngII. Synthetically pure TP1 significantly reduced the capacity of AT1R to bind AngII without affecting AngII binding to AT2R, demonstrating an AT1R selective effect. TP1 reduced AngII-induced calcium signaling and migration in AT1R-expressing cells, arterial contraction, and increases in blood pressure in AngII-infused mice, demonstrating its activity as a NAM. Crucially, TP1 blocked binding of pathogenic autoantibodies to AT1R-expressing cells from the serum of patients with preeclampsia and dilated cardiomyopathy, a function distinct from ARBs. Together, these findings establish TP1 as a proof-of-concept, AT1R-selective NAM chemotype with therapeutic potential for AT1R autoantibody-driven conditions such as preeclampsia, where ARBs are strictly contraindicated. Developing AT1R-targeted NAM antihypertensive drugs may offer therapeutic advantages over ARBs and expand the pharmacological toolkit for this important CVD receptor. Key words: AT1R, AngII, AT1R-AAb, NAM, Allosteric ligand, GPCR, blood pressure, pharmacokinetics, antihypertensives

Explore related subjects

pharmacology and toxicologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Singh, K. D., Pardhi, T. R., Harford, T. J., Laishram, L., Ravi, T., Desnoyer, R., Maroo, A. P., Tang, W. W. H., Karnik, S. S.. 2026-10-13. AT1R-Selective Negative Allosteric Modulator Targeting the Epitope for Pathogenic Autoantibody Activation. https://doi.org/10.64898/2026.10.12.758523

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

A mechanistic classification of GNAO1 mutations links Gβ γ sequestration to hyperkinetic disease and treatment response

Go is the most prevalent G protein subunit in the brain and is critical for signal transduction through G protein-coupled receptors. Mutations in the gene encoding Go (GNAO1) cause a rare neurodevelopmental disorder with involuntary movements (NEDIM) and, in some patients, developmental and epileptic encephalopathy (DEE). Here, we integrate human genetic analysis with cellular assays to define mechanistic classes of GNAO1 mutations and in vivo approaches to evaluate therapeutic strategies. We grouped variants into two functional categories: those predicted to sequester G{beta}{gamma} and those with reduced Go expression and therefore increased G{beta}{gamma} signaling. Analysis of patient data revealed that mutations predicted to impair G{beta}{gamma} release are significantly associated with NEDIM. Using the GNAO1R209H/+ mouse as a model of NEDIM, we evaluated two small molecules: caffeine, a nonselective adenosine receptor antagonist, and gallein, a selective modulator of G{beta}{gamma}-effector interactions. Both compounds significantly reduced hyperlocomotion in the open field test. Whole-cell patch-clamp electrophysiology revealed sex- and cell type-specific hyperexcitability in spiny projection neurons within the dorsolateral striatum of GNAO1R209H/+ mice. Together, these findings implicate dysfunction of dorsolateral striatal pathways in GNAO1-related disorder and suggest that mechanistic understanding of disease variants can guide targeted therapeutic strategies.

pharmacology and toxicology↗
bioRxiv2026

Screening and evaluation of medicine food homology herbal combinations for ameliorating chemotherapy induced ovarian aging under an integrated multi-strategy framework

Abstract Background: Ovarian aging poses a serious threat to women's reproductive health. Medicine food homology (MFH) herbs, owing to their favorable safety profile and suitability for long-term use, have become important interventional resources. However, conventional formula screening relies largely on empirical statistics and lacks mechanistic evidence and a systematic screening strategy. Methods: In this study, we integrated single cell transcriptomic analysis, human use evidence mining, UPLC/Q TOF MS chemical profiling and pretrained protein molecular representation models to establish a multi strategy framework for the discovery of MFH herbal combinations. Single cell transcriptomic datasets related to ovarian aging from the GEO database were analyzed to identify key pathological processes and candidate targets. High-frequency MFH herbs were selected by mining classical prescriptions and clinical literature. By comparing six protein molecular pretrained representation combinations, ESM T5 was identified for compound target affinity prediction and validated by molecular dynamics simulation and surface plasmon resonance (SPR) assays, ultimately identifying the Astragalus ginseng (Huangqi Renshen) herb pair (HXF) as the core candidate. Functional expression validation of key targets was performed, and the efficacy of HXF and the expression of related molecules were verified in a D gal induced KGN granulosa cell senescence model and a cyclophosphamide-induced rat model of diminished ovarian function. Results: Single cell analysis revealed that ovarian aging was characterized by impaired steroidogenesis, enhanced MDK NCL communication between granulosa cells and immune cells, and extracellular matrix remodeling, with CYP19A1, SERPINE1 and MDK as key targets. By further integrating human-use evidence mining and UPLC/Q TOF MS compound annotation, an MFH compound library comprising 712 molecules was established. ESM T5 prediction, molecular dynamics (MD) simulation and SPR assays confirmed that multiple constituents of Astragalus and ginseng exhibited favorable binding activity toward key targets. At the cellular level, knockdown of MDK or SERPINE1 attenuated the senescence phenotype, whereas knockdown of CYP19A1 aggravated it. In vitro and in vivo experiments demonstrated that Astragalus ginseng ameliorated granulosa cell senescence and diminished ovarian function in rats, restored CYP19A1 related steroidogenesis, downregulated inflammation- and matrix remodeling related molecules such as SERPINE1 and IL18, and reduced MDK NCL colocalization signals. Conclusion: This study established a multi-strategy screening framework integrating disease mechanism decoding, human use evidence constraints and pretrained model prediction, and identified Astragalus ginseng as a candidate herb pair for ameliorating ovarian aging. Its effects may be associated with promoting steroidogenesis, suppressing SERPINE1/IL18 related inflammation and matrix remodeling, and modulating MDK NCL signaling. These findings provide a strategic reference for the mechanism oriented discovery of MFH herbal combinations.

pharmacology and toxicology↗
bioRxiv2026

BRET-Based Ligand Binding at Recombinant and Endogenous Dopamine D2 Receptors

Dopamine D2 receptor (D2R) regulates diverse biological processes and is an important therapeutic target, underscoring the need for robust methods to quantify ligand binding at this receptor. Bioluminescence resonance energy transfer (BRET)-based ligand binding assays have emerged as a powerful platform for quantifying binding in living cells, but their application to D2R has been limited by the availability of suitable fluorescent tracers. Here, we developed three far-red fluorescent antagonists (CELT-240, CELT-383, and CELT-385) as BRET tracers for D2R. All three compounds produced specific, saturable D2R binding with nanomolar affinity. Further characterization of CELT-385 demonstrated its utility for kinetic and competition binding measurements and revealed high affinity binding at the closely related dopamine D3 receptor (D3R). We also extended BRET-based ligand binding beyond genetically-modified receptors using bystander BRET, enabling measurements at unmodified recombinant and endogenously expressed D2R. Together, these findings provide new tools for quantitative D2R/D3R ligand binding and a template for extending BRET-based ligand binding to endogenously expressed GPCRs.

pharmacology and toxicology↗